TechFlow, May 7 — According to Decrypt, NewLimit, a biotech company co-founded by Coinbase CEO Brian Armstrong, has announced the completion of a $130 million Series B funding round led by Kleiner Perkins. The company uses AI and genomics to research ways to slow down and reverse human aging through cellular reprogramming. With this round, NewLimit has raised over $170 million in total funding. Its "discovery engine" can test thousands of reprogramming combinations.
Navigating Web3 tides with focused insights
Contribute An Article
Media Requests
Risk Disclosure: This website's content is not investment advice and offers no trading guidance or related services. Per regulations from the PBOC and other authorities, users must be aware of virtual currency risks. Contact us / support@techflowpost.com ICP License: 琼ICP备2022009338号




